
Olinvyk is the first new chemical entity in this IV drug class in decades.

Researchers reviewed the evidence of the association between vitamin D and multiple sclerosis.

A recent study found 64% of patients with psoriatic arthritis who had tried at least one biologic stayed with Cosentyx for the entire study period.


Next generation PBMs like Flipt and RxSense are challenging the "old guard" PBMs that control three-quarters of the market.

Adaptive Biotechnologies’ clonoSEQ gets third approval; FDA also acts on first at-home treatment for spinal muscular atrophy.

In this part two of two video series Adam Block discusses his recent article, “Profits of Publicly Traded Health Plans Surge Amid Requests for Higher Rates.”

Dovato lets adults with HIV reduce the number of antiretroviral therapies they take, while maintaining efficacy and a high barrier to resistance comparable to tenofovir-based regimens.

In this part one of two video series, Adam Block, a New York Medical College assistant professor, discusses his recent contributed article to Managed Healthcare Executive titled "Profits of Publicly Traded Health Plans Surge Amid Requests for Higher Rates."

Double-blind study will compare Rebif-remdesivir combination with remdesivir-alone in hospitalized COVID-19 patients

The highly respected healthcare industry veteran will bring his signature team building skills, track record of double-digit revenue growth and subject matter expertise in diabetes.

In this part two of two series, Carolyn Langer, M.D., Fallon Health's chief medical officer, talks about Collective Medical and the advantages of real-time notifications of member hospital admissions and discharges and emergency department visits.

This week on Tuning Into The C-Suite, Managed Healthcare Executive Senior Editor Peter Wehrwein speaks with Assistant Professor of Public Health at New York Medical College, Adam Block. The two discuss Block's recent article published in MHE, "Profits of Publicly Traded Health Plans Surge Amid Requests for Higher Rates" and more.

Amid struggling providers, furloughs of essential workers, years of premium increases and record high earnings, for-profit health plans should consider options for directly helping their networks.

Research model shows that caps on out-of-pocket costs don't result in higher health plan spending.

In this part one of two series, Carolyn Langer, M.D., the chief medical officer, says the Massachusetts health plan mounted a big push on telehealth that includes in-person visit payment levels.

The American College of Cardiology issues its second set of recommendations for its members on prescribing two groups of drugs first developed for type 2 diabetes.

It's early days yet because patent and other issues have kept FDA-approved biosimilars off the market, but Gary Lyman, M.D., M.P.H.. of the Fred Hutchinson Cancer Research Center says there's evidence of some effect on the price of cancer supportive drugs.

The chimeric antigen receptor (CAR) T cell therapy is the first of its kind for mantle cell lymphoma (MCL).

Many are anxious or down but finding silver linings amidst challenges; essential workers and boomers are faring better than most.

Esketamine (Spravato) can now be used to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

Before COVID-19, half of families with employer-sponsored insurance delayed care or avoided filling a prescription. Recent data shows consumers face barriers to care.

Lives can be saved, physician burnout and waste can be reduced, and drug costs can decrease by achieving medication optimization through comprehensive medication management.

Shielding means staying at home and limiting contact with members of the household. Research also calls into question on how effective it is in reducing the incidence of COVID-19.

Content of this article was sponsored by Arbor Pharmaceuticals, LLC. Copyright 2020. This Managed Healthcare Executive® publication provides key information regarding a review by Faraone, et al, which was originally published in the Journal of the American Academy of Child & Adolescent Psychiatry (doi: 10.1016/j.jaac.2019.06.012). The authors of the original review are Stephen V. Faraone, PhD; Anthony L. Rostain, MD; C. Brendan Montano, MD; Oren Mason, MD; Kevin M. Antshel, PhD; Jeffrey H. Newcorn, MD. Please consult the full published review for complete information.

Preliminary findings by Case Western researchers point to kallikrein-related peptidase 6 as possible culprit in the development of psoriatic arthritis.

In a busy week, FDA approved ground-breaking therapies in hematologic cancers and issued Orphan Drug designations in areas of significant unmet need.

COVID-19 spotlights the threat that cardiovascular disease poses to Americans; new technology may help address risk factors at the population health level.

Artificial intelligence and machine learning can take on simple tasks in healthcare so people can focus on collaboration and work on a higher cognitive level.

As it has done with so much else in healthcare, COVID-19 dominated our 2020 annual pharmacy survey. The disease was addressed in 10 of our 13 areas we covered, either within the question itself or as a possible answer. Third of three parts. See more in our Surveys tab.